Soquelitinib

Overview

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase ( ITK ) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Itk

Product Information

• Catalog No.: HY-150298
• CAS No.: 2226636-04-8
• Molecular Formula: C25H30N4O4S2
• Molecular Weight: 514.66
• Purity: 99.98%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 10 mg/mL (19.43 mM); Clear solution
• Availability: In-stock

Source

Original product source